Details

Autor(en) / Beteiligte

• Autore, Francesco
• Innocenti, Idanna
• Reda, Gianluigi
• Visentin, Andrea
• Vitale, Candida
• Piciocchi, Alfonso
• Fresa, Alberto
• Leone, Monica M. A.
• Farina, Lucia
• Quaresmini, Giulia
• Baratè, Claudia
• Giordano, Annamaria
• Ferrari, Angela
• Angeletti, Ilaria
• Paolis, Maria Rosaria
• Malerba, Lara
• Chiurazzi, Federico
• Loseto, Giacomo
• Catania, Gioacchino
• Sportoletti, Paolo
• Scortechini, Ilaria
• Moia, Riccardo
• Gentile, Massimo
• Rigolin, Gian Matteo
• Mattiello, Veronica
• Gattei, Valter
• Coscia, Marta
• Trentin, Livio
• Foà, Robin
• Cuneo, Antonio
• Laurenti, Luca

Titel

Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study

Ist Teil von

• Hematological oncology, 2023-12, Vol.41 (5), p.877-883

Ort / Verlag

England: Wiley Subscription Services, Inc

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Clinical or biological parameters useful to predict progression during treatment in real‐life setting with ibrutinib, idelalisib and venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) are still debated. We conducted a multi‐center retrospective study on CLL patients treated with ibrutinib and/or idelalisib who were switched to venetoclax for progression or due to adverse events to identify any clinical and/or biological parameters useful to predict progression during treatment with venetoclax. Of all the 128 evaluable patients, 81 had received ibrutinib prior to switching to venetoclax, 35 had received idelalisib and 12 both. When comparing the three subgroups, we did not notice any statistical difference in terms of clinical or biological features. No variable at baseline and at different time points during the follow‐up (at 6, 12, 18 and 24 months) was found to predict progression nor to have significance for Progression Free Survival (PFS) in the ibrutinib group and in the idelalisib group and in subgroups according to the line of treatment. Analyzing the data of the venetoclax treatment, after a median follow up of 14.3 months, median PFS was not reached and estimated 3‐year PFS was 54%. Of the 128 patients treated with venetoclax, 28 (22%) experienced progressive disease. At multivariate analysis for predictive factors for progression, lymph node diameter >56.5 mm before starting treatment emerged as an independent risk factor for progression. The lymph node predictive role for progression during venetoclax treatment could be a new parameter that deserves to be investigate in future studies.